Linked Life Data

12234701

Source:http://linkedlifedata.com/resource/pubmed/id/12234701

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-9-17
pubmed:abstractText
This randomized study of previously untreated patients with extensive disease small cell lung cancer was designed (a) to compare the survival of patients treated with either effective standard chemotherapy or an investigational anti-cancer drug as initial therapy and (b) to evaluate response rates and toxic effects of such therapies. One hundred and thirty-five patients were randomly assigned to receive as initial therapy, either the standard CAV regimen--cyclophosphamide (1000 mg/m(2)), doxorubicin (50 mg/m(2)) and vincristine (1.4 mg/m(2)) every 3 weeks--or the phase II drugs ifosfamide (1.5 gm/m(2)/days 1-5) with mesna (300 mg/m(2)) dose at 0, 4 and 8 h after IV daily ifosfamide every 3 weeks or teniposide (60 mg/m(2)/days 1-5) every 3 weeks. Nonresponders received salvage chemotherapy-etoposide (120 mg/m(2) on days 1, 2 and 3) and cisplatin (60 mg/m(2) on day 1), repeated every 3 weeks. Among the 46 patients on CAV, there were two complete and 24 partial responses (56%). Among the 43 patients on ifosfamide, there were three complete and 18 partial responses (49%), while among the 46 patients on teniposide, there were two complete and 18 partial responses (43%). Eighty-three of the patients proceeded onto salvage regimen, of which 81 were analyzable for response and toxicity. Among the 81 patients who continued on salvage therapy and were evaluable for response, the overall best response rate was 61% for CAV+salvage, 54% for ifosfamide+salvage, and 53% for teniposide+salvage. These rates were not significantly different (P=0.962). Of the 135 analyzable patients, 130 (96%) have died. The estimated median survival time was 42 weeks for CAV patients, 43 weeks for ifosfamide, and 38 weeks for teniposide. Seven patients survived longer than 2 years (four on CAV, one on ifosfamide and two on teniposide). There were 29 life-threatening complications to the induction regimen (22 (48%) on CAV, four (9%) on ifosfamide and three (7%) on teniposide) and seven lethal complications (two on CAV, four on ifosfamide and one on teniposide). The treatments were significantly different with respect to the overall degree of toxicity (P < 0.0001) with CAV being more toxic. The data of this study, like the previous ECOG study suggests that the administration of a new agent followed by effective salvage chemotherapy in the treatment of extensive disease small cell lung cancer may have no adverse effect on survival.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0169-5002
pubmed:author
pubmed:copyrightInfo
Eastern Cooperative Oncology Group
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12234701-Adult, pubmed-meshheading:12234701-Aged, pubmed-meshheading:12234701-Antineoplastic Agents, pubmed-meshheading:12234701-Antineoplastic Agents, Alkylating, pubmed-meshheading:12234701-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12234701-Carcinoma, Small Cell, pubmed-meshheading:12234701-Cyclophosphamide, pubmed-meshheading:12234701-Doxorubicin, pubmed-meshheading:12234701-Female, pubmed-meshheading:12234701-Humans, pubmed-meshheading:12234701-Ifosfamide, pubmed-meshheading:12234701-Infusions, Intravenous, pubmed-meshheading:12234701-Lung Neoplasms, pubmed-meshheading:12234701-Male, pubmed-meshheading:12234701-Middle Aged, pubmed-meshheading:12234701-Neoplasm Staging, pubmed-meshheading:12234701-Salvage Therapy, pubmed-meshheading:12234701-Survival, pubmed-meshheading:12234701-Teniposide, pubmed-meshheading:12234701-Treatment Outcome, pubmed-meshheading:12234701-Vincristine
pubmed:year
2002
pubmed:articleTitle
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588).
pubmed:affiliation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room G-88, 1650 Orleans Street, Baltimore, MD, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Multicenter Study